Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy

NCT ID: NCT02969278

Last Updated: 2016-11-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-07-31
• Study Completion Date: 2017-07-31

Brief Summary

The study aim is to verify the accuracy of SNB combined with 18F-FDG PET/CT in cN0 invasive vulvar cancer (IVC) patients currently not candidate to SNB according to standard guidelines.

Detailed Description

Vulvar carcinoma (VC) is a rare disease (4% of gynecological cancers) and the treatment is not yet universally defined. No official guidelines are currently available to define imaging techniques useful for staging. In the pre-operative evaluation of the pateints, imaging should assess nodal status; the available exams are:

• CT or MRI with contrast (abdominal and pelvic with caudal scans for inguinal regions)
• Inguinal ultrasound with US-guided biopsy/fine needle aspiration for suspicious lymph nodes.

The incidence of inguinal and pelvic lymph node metastasis not diagnosed at the pre-operative imaging is 10-35% as assessed after lymphadenectomy at pathology report.

Until 2009, the standard surgical treatment of vulvar cancer was represented by mono or bilateral systematic lymphadenectomy (at least 70% of N0 women underwent a radical surgery with the risk of severe morbidity related to the surgical procedure with no survival benefit).

Inguinal lymphadenectomy shows a high rate of local and systemic complications resulting in a longer hospitalization or recovery, as well as possible delays in adjuvant therapies.

Moreover, severe complications can lead to a further surgery.

Possibile complications described in literature are:

• Lymphedema (up to 70%)
• Infection and postoperative cellulitis (50%)
• Inguinal suture dehiscence (between 22 and 52%)
• Linfocysts (between 7 and 28%)
• Deep vein thrombosis (between 5 and 8%)
• Sepsis (1 -2%)

Since 2009, with the introduction and the validation of sentinel node biopsy (SNB), for some VC it is now possible to obtain a nodal staging with minimally invasive surgery and lower morbidity. However, the SNB technique is indicated if the tumor fits the following selection criteria:

• Infiltrating tumors with a diameter < 40 mm;
• Monofocal tumors;
• Tumors distant more than 1 cm from the midline
• Tumors near the midline with bilateral lymphatic drainage and intraoperative detection of at least one sentinel node for each groin.

Consequently in many tumors diagnosed as N0 at preoperative imaging, SNB technique is not indicated; these tumors still require systematic lymphadenectomy.

In this subset of patients it is important to identify new methods for preoperative evaluation of nodal status or to define a sub-category of patients for which the SNB could be applied.

Objective of the study is to verify, in patients actually off-label for SNB, the accuracy of 18FDG-PET/CT in predicting nodal status, as an indipendent method or associated with the standard pre-operative imaging and the mini-invasive surgical staging.

All patients are submitted to:

• Gynecologic visit
• Vulvar biopsy and possible pelvic examination under anesthesia with the definition of clinical extent of disease
• Evaluation of serum tumor markers: SCC and Ca125
• Inguinal ultrasound and possible US guided FNAC or FNAB on suspicious lymph nodes
• CT scan (abdomen and pelvis) with contrast
• 18FDG-PET/CT
• Lymphangioscintigraphy of inguinofemoral axis

Vulvar surgery may include:

• Wide resection of vulvar disease
• Emivulvectomy (anterior, posterior or lateral)
• Simple vulvectomy
• Radical or ultra-radical vulvectomy (with possible plastic reconstruction)

During inguinal surgery all patients will undergo:

• Sentinel node biopsy mono or bilateral followed by radical bilateral inguinal lymphadenectomy

Statistical analysis will help determine the accuracy and negative predictive value of FDG-PET/CT and sentinel node biopsy in predicting nodal status.

Conditions

Vulvar Cancer

Keywords

vulvar cancer; sentinel node biopsy; inguino-femoral lymphadenectomy; 18F FDG- PET/TC; guidelines; preoperative imaging

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vulvar cancer patients cN0 unfit for sentinel node biopsy

All invasive vulvar cancer patients with cN0 status:

• T > 4 cm;
• multicentric tumors (mono or bilateral);
• primary lesion completely excised during prior diagnostic surgery
• patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0
• previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy

Group Type: EXPERIMENTAL

18FDG-PET/TC

Intervention Type: PROCEDURE

Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes

Sentinel node biopsy

Intervention Type: PROCEDURE

Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.

Interventions

18FDG-PET/TC

Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes

Intervention Type: PROCEDURE

Sentinel node biopsy

Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Age> 18 years
• ECOG ≤ 2
• Adequate respiratory, hepatic, cardiac, bone marrow and renal function (creatinine clearance> 60 mL/min according to the Cockroft formula)
• Patient psychologically able to follow the study procedures
• Signature of informed consent

In addition, both major criteria and at least one of the minor criteria must be present:

MAJOR CRITERIA

• Vulvar carcinoma (stromal infiltration > 1 mm); Histotypes different from squamous are included
• Negative lymphnodes at preoperative imaging

MINOR CRITERIA

• Vulvar lesion greater than 4 cm
• Multifocal or bilateral lesions
• Previous complete excisional biopsy of the vulvar lesion, with absent residual disease
• Previous neoadjuvant treatment (radiotherapy a/o sequential/concomitant chemotherapy)
• Previous treatment with radiotherapy a/o chemotherapy (sequential a/o concomitant) for previous vulvar cancer a/o other diseases
• Previous vulvar or inguinal surgery
• Infiltrating vulvar carcinoma with monolateral groin lymphnode involvement (N1) and contralateral N0

Exclusion Criteria

• Allergy to egg proteins and albumin
• Pregnancy and breastfeeding
• Patients with impaired respiratory, hepatic, cardiac, bone marrow and renal function (creatinine clearance> 60 mL / min according to the Cockroft formula)
• Patients with major depressive disorder

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Catholic University of the Sacred Heart

OTHER

Sponsor Role: lead

Responsible Party

Prof. Giovanni Scambia

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Division of Gynecologic Oncology/Fondazione Policlinico Gemelli

Rome, Rome, Italy

Site Status: RECRUITING

Countries

Italy

Facility Contacts

Giorgia Garganese, MD

Role: primary

Simona M Fragomeni, MD

Role: backup

Other Identifiers

GroSNaPET

Identifier Type: -

Identifier Source: org_study_id